Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prices Could Be Slashed Under U.K.’s New Drug-Pricing Scheme

This article was originally published in The Pink Sheet Daily

Executive Summary

Prices may decrease, but at least wider societal benefits are to be included in NICE’s assessment in the U.K.’s new value-based pricing (VBP) scheme for new pharmaceuticals, a change long demanded by critics of the health technology assessment body.

You may also be interested in...



Pharma Hopes EU Commission Policy Report Will Lead To Real Dialogue

The European Commission's latest policy document dedicated to making the pharma industry a better global competitor advocates a new, co-operative approach, but lacks detail. The industry, though, believes the document offers hope for constructive debate in key areas.

Pharma Hopes EU Commission Policy Report Will Lead To Real Dialogue

The European Commission's latest policy document dedicated to making the pharma industry a better global competitor advocates a new, co-operative approach, but lacks detail. The industry, though, believes the document offers hope for constructive debate in key areas.

Pharma Hopes EU Commission Policy Report Will Lead To Real Dialogue

The European Commission's latest policy document dedicated to making the pharma industry a better global competitor advocates a new, co-operative approach – but it lacks detail.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS075862

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel